Claim being checked · Version 1 · Reviewed
“Elamipretide improved walking distance and fatigue in the large phase 3 mitochondrial-myopathy trial.”
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
No dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Misleading. This statement leaves out a limit that changes its meaning.
Answer scope
This verdict checks the exact claim in the heading. It is not a universal grade for SS-31.
01 · Answer
Misleading
The 24-week MMPOWER-3 trial did not meet its main goals for six-minute walk distance or fatigue compared with placebo.
- What kind of evidence this is
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- What this answer covers
- The 218 adults with genetically confirmed primary mitochondrial myopathy studied in MMPOWER-3 for 24 weeks. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
- Question type
- Clinical outcomes. What a study measured about people's health, symptoms, or ability to function.
02 · Sources
Read the sources behind this answer
- Editorial review
- Internal editorial review recorded
- Source review
- Anthony Treviso · Founder and responsible editor
- Medical review status
- Not independently medically reviewed. Editorial source review does not replace medical review.